Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Following the acquisition of Varian Medical Systems, Inc. the company has approximately 66,000 employees worldwide.
The Atellica® Decapper integrates decapping into the analytical workflow of Atellica Solution with little to no additional footprint to accommodate workflow and space requirements. It removes caps for the majority of the tubes that are validated on the Atellica Solution and can be part of the initial installation or added to existing configurations with multiple placement possibilities. Up to three Atellica Decappers can be integrated into a single Atellica Solution configuration in any of three location options. Location is determined by the workflow needs of the lab.
The Atellica® NEPH 630 System is a dedicated nephelometric system that simplifies lab operations by offering the broadest menu of protein tests on multiple sample types. Part of the Atellica family, it streamlines workflow with highly intelligent software and provides smart, simple, secure testing.
Siemens Healthineers provides clinicians with a high-sensitivity cardiac troponin I assay that aids in the diagnosis of acute myocardial infarction. We offer the TNIH assay in various platforms as Atellica IM Analyzer, ADVIA Centaur systems and Dimension® EXL™. The Atellica IM & ADVIA Centaur High-Sensitivity Troponin I (TnIH) Assay is an in vitro diagnostic immunoassay for the quantitative determination of cTnI in lithium heparin (LiHep) plasma or serum (no EDTA). The Dimension® EXL™ LOCI® TNIH assay is a homogeneous, sandwich chemiluminescent immunoassay based on LOCI technology. High-sensitivity cardiac troponin I (hs-cTnI) assay provides more accuracy and precise measurement changes in cTnI concentrations in serial blood draws and provides useful data to assist in identifying acute versus chronic cTnI elevations and acceptable rule-in and rule-out performance within 1 to 3 hours of presentation. It will help to rule-in or rule-out of acute myocardial infarction (AMI) in patients and for the management of NSTEMI.
Siemens Healthineers offers SARS-CoV-2 Total (COV2T) Antibody Assay in Atellica IM & ADVIA Centaur. COV2T test provides a more complete picture of a patient’s serological status throughout his or her continuum of care. The COV2T assay detects both IgM and longer-lasting IgG antibodies. Siemens Healthineers SARS-CoV-2 Total (COV2T) test is designed to detect the spike protein receptor-binding domain (S1 RBD) on the surface of the SARS-CoV-2 virus, which binds the virus to cells via a distinct human receptor (ACE2) found in the lungs, heart, and multiple organs and blood vessels. Evidence shows that many antibodies to the spike protein are neutralizing—an important link for vaccine development and investigation of potential immunity following resolved infection. Multiple vaccine programs target S1 RBD, and antibodies (immune response) may be used as a surrogate endpoint of vaccine efficacy.